BLCO

Bausch + Lomb Corporation

Fundamental data last updated:June 19, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NYSE

County of HQ

CA

Next Earnings Date

07/29/2026

Business Summary

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

 


VALUATION

P/E

-25.29

Market Cap ($M USD)

$5.56B

Forward P/E

8.76

PEG

0.02

PRICE TO SALES

1.07

PRICE TO BOOK

0.87

EV / EBITDA

7.36

5-Year Average P/E

Free Cash Flow Yield

0.08%

DCF Value

$9.35

Graham Number

N/A

Price to FCF

1283.91

EV to FCF

1231.02

Earnings Yield

-3.95%

FCF Yield

0.08%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.62

Next Year EPS Growth Estimate

$1.78

Next Year Revenue Growth Estimate

$592.87B

Return on Equity (ROE)

-3.41%

FREE CASH FLOW

Operating Margin

5.91%

Debt-to-Equity

0.83

Piotroski F-Score

5

Altman Z-Score

0.89

Return on Invested Capital (ROIC)

2.58%

Current Ratio

1.53

Quick Ratio

0.99

Net Debt to EBITDA

-0.32

Interest Coverage

0.71

Gross Profit margin

55.86%

FCF PER SHARE

$0.01

REVENUE PER SHARE

$14.66

Gainseekers Quantitative Analysis

Summary

BLCO’s valuation paints a complex picture. Recent pricing indicated it traded above its DCF value, suggesting potential overvaluation. However, the Forward P/E of 9.09 hints at optimism for future earnings, contrasting sharply with the negative Earnings Yield and a precarious Altman Z-score of 0.91, which signals financial distress. The market seems to be betting on a turnaround, but the negative ROE and EPS raise red flags about current profitability. This stock is a gamble on future growth rather than present stability.

AI Exposure / Tech Reliance

Operating in the Medical Instruments & Supplies industry, BLCO is well-positioned to leverage AI for enhanced precision and efficiency in its products. The healthcare sector's increasing reliance on technology provides a fertile ground for innovation. However, the company must continuously adapt to remain competitive in this rapidly evolving landscape.

The Bull Case

For the value-driven investor, BLCO offers intriguing prospects. With a Piotroski F-Score of 5, it shows moderate financial health, while a low Price/Book ratio of 0.90 suggests undervaluation. The company's ROIC of 2.58% and operating margin of 5.91% indicate decent capital efficiency and pricing power. Despite a meager FCF Yield, the potential for significant sales growth next year could unlock value for patient investors.

The Bear Case

Yet, the bear case is hard to ignore. The negative EPS and Earnings Yield highlight profitability issues, while the Altman Z-score suggests financial instability. The Price to FCF ratio of 1332.50 is alarmingly high, indicating poor cash flow generation relative to its market price. Additionally, trading close to its 52-week high, the stock appears technically overextended, raising concerns about its sustainability at these levels.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$18.88

Institutional Ownership %

1-Year Beta

0.59

Insider Buying % (6 Mo)

Distance to 52-Week High

21.33%

Distance to 52-Week Low

28.03%

EARNINGS SURPRISE %

33.33%

50-DAY SMA

$16.10

200-DAY SMA

$16.08

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.